<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02656173</url>
  </required_header>
  <id_info>
    <org_study_id>178-MA-3016</org_study_id>
    <nct_id>NCT02656173</nct_id>
  </id_info>
  <brief_title>A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH)</brief_title>
  <official_title>A Phase 4, Double-Blind, Randomized, Placebo-controlled Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With OAB Symptoms, While Taking the Alpha Blocker,Tamsulosin, for BPH</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma Singapore Pte. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to investigate the efficacy of mirabegron versus
      placebo in male patients with OAB symptoms while taking the alpha blocker, tamsulosin, for
      BPH.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 25, 2016</start_date>
  <completion_date type="Actual">July 21, 2017</completion_date>
  <primary_completion_date type="Actual">July 21, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in mean number of micturitions per 24 hours</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Symptom Bother and Total Health-Related Quality of Life scores, as assessed by the OAB questionnaire</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of treatment-emergent adverse events</measure>
    <time_frame>Up to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by Vital signs</measure>
    <time_frame>Up to Week 12</time_frame>
    <description>Vital signs: sitting systolic and diastolic blood pressure and pulse rate (home based self-measurements and office measurements)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by Laboratory parameters</measure>
    <time_frame>Up to Week 12</time_frame>
    <description>Laboratory parameters: serum chemistry, hematology, and urinalysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Post-voiding residual urine volume</measure>
    <time_frame>Baseline to Week 4, Week 8 and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Maximum urine flow rate</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean number of urgency episodes per 24 hours</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean number of urgency incontinence episodes per 24 hours</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean number of incontinence episodes per 24 hours</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean number of nocturia episodes</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean volume voided per micturition</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in total OABSS</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>OABSS: overactive bladder symptom score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in subscale score from OABSS</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in total IPSS</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>IPSS: international prostate symptom score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in subscale score from IPSS</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">730</enrollment>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>Mirabegron group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirabegron</intervention_name>
    <description>Oral</description>
    <arm_group_label>Mirabegron group</arm_group_label>
    <other_name>YM178</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        at Visit 1 (Screening):

          -  Patient has been under treatment with tamsulosin 0.2mg for at least 4 weeks before the
             start of the Screening period

          -  Patient with a history of an average of at least 2 episodes of urgency per 24 hours
             and an average of 8 or more micturitions per 24 hours during the last 3 days before
             the start of the Screening period (verified by interview).

          -  Patient who has no wish to have children in the future (Unique to Japan).

          -  Male subjects and their female spouses/partners who are of childbearing potential must
             be using highly effective contraception consisting of two forms of birth control (at
             least one of which must be a barrier method), starting at Screening, continuing
             throughout the study period, and for 28 days after the final study drug
             administration.

          -  Subject must not donate sperm, starting at Screening, continuing throughout the study
             period, and for 28 days after the final study drug administration.

          -  Patient is willing and able to complete the micturition diary and questionnaires
             correctly.

          -  Subject agrees not to participate in another interventional study while receiving
             treatment in this study.

        at Visit 2 (Baseline):

          -  Subject with an average of at least 2 episodes of urgency per 24 hours and an average
             of 8 or more micturitions per 24 hours based on a 3-day micturition diary from the
             Screening period.

        Exclusion Criteria:

        at Visit 1 (Screening):

          -  Patient with suspected symptoms of OAB, with onset only transient (e.g., drug-induced,
             psychogenic).

          -  Patient with PVR urine volume &gt;100 mL or Q max &lt;5 mL/sec.

          -  Patient with prostate-specific antigen (PSA) â‰¥4 ng/mL.

          -  Patient with neurogenic bladder (e.g., spinal-cord lesions or other damage that will
             clearly affect urination; multiple sclerosis; Parkinson's disease) or a history of
             surgery that caused damage to the pelvic plexus.

          -  Patient with urethral stricture or bladder-neck stenosis.

          -  Patient with diabetic neuropathy complications.

          -  Patient who has undergone a surgical procedure, previous pelvic radiation therapy, or
             hyperthermia therapy that may affect urinary tract function.

          -  Patient with significant stress incontinence or postsurgical prostate incontinence, as
             determined by the Investigator.

          -  Patient with an indwelling catheter or practices intermittent self-catheterization.

          -  Patient with 3 or more episodes of recurrent urinary tract infection (UTI) within the
             last 6 months.

          -  Patient with a UTI; prostatitis; chronic inflammation, such as interstitial cystitis;
             urinary calculus; or previous or current malignant disease of the pelvic organs.

          -  Patient with a concurrent malignancy or history of any malignancy (within the past 5
             years), except for non-metastatic basal-cell or squamous-cell carcinoma of the skin
             that has been treated successfully.

          -  Patient with serious heart disease, liver disease, kidney disease, immunological
             disease, lung disease.

          -  Patient who has received intravesical injection within the last 12 months with
             botulinum toxin, resiniferatoxin, or capsaicin.

          -  Patient who has received electrostimulation therapy for OAB.

          -  Patient who has received a bladder training program or pelvic floor exercises &lt;28 days
             prior to the start of the Screening period.

          -  Patient with postural hypotension or syncope, hypokalemia, or closed-angle glaucoma.

          -  Patient with evidence of QT prolongation on electrocardiogram (ECG), defined as QTcF
             &gt;450 msec.

          -  Patient with severe uncontrolled hypertension, defined as sitting systolic blood
             pressure (SBP) &gt;180 mmHg and/or diastolic blood pressure (DBP) &gt;110 mmHg.

          -  Patient with a clinically significant ECG abnormality, as determined by the
             Investigator.

          -  Patient who has severe renal impairment, defined as an estimated glomerular filtration
             rate of &lt;29 mL/min/1.73m2; end-stage renal disease; or is undergoing dialysis.

          -  Patient with aspartate transaminase (AST) or alanine transaminase (ALT) &gt;2 times the
             upper limit of normal (ULN), or gamma-glutamyl transferase (Î³-GT) &gt;3 times the ULN and
             considered clinically significant by the Investigator.

          -  Patient with moderate or severe hepatic impairment, defined as Child-Pugh Class B or
             C.

          -  Patient with hypersensitivity to any of the components of mirabegron, other
             beta-adrenergic receptor (Î²-AR) agonists, or any of the inactive ingredients.

          -  Patient with ongoing alcohol and/or drug abuse.

          -  Patient with or a history of mood disorder, neurotic disorder, or schizophrenia.

          -  Patient with dementia, cognitive dysfunction, or clinically significant
             cerebrovascular disorder.

          -  Patient who has been treated with an experimental device &lt;84 days or received an
             investigational agent &lt;84 days prior to the start of the Screening period.

          -  Patient has used any prohibited concomitant medication &lt;28 days (but, &lt;1 year for
             5Î±-reductase inhibitors) before the start of the Screening period.

          -  Patient with any clinically significant condition, which in the opinion of the
             Investigator, makes the subject unsuitable for study participation.

          -  Patient who is involved in the conduct of the study as an employee of the Astellas
             group, a third party associated with the study, or the study site team.

        at Visit 2 (Baseline):

          -  Subject fulfills any exclusion criteria of Visit 1 at Visit 2.

          -  Subject was noncompliant during the 4 week tamsulosin Screening period, defined as
             taking less than 80% or greater than 120% of prescribed dose of study medication.

          -  Subject had an average total daily urine volume &gt;3000 mL, as recorded in the 3-day
             micturition diary.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site JP81046</name>
      <address>
        <city>Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81009</name>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81045</name>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81041</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81042</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81043</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81044</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81048</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81004</name>
      <address>
        <city>Gunma</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81005</name>
      <address>
        <city>Gunma</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81001</name>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81002</name>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81003</name>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81038</name>
      <address>
        <city>Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81039</name>
      <address>
        <city>Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81040</name>
      <address>
        <city>Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81024</name>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81056</name>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81051</name>
      <address>
        <city>Kochi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81052</name>
      <address>
        <city>Kochi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81047</name>
      <address>
        <city>Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81025</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81026</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81027</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81028</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81029</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81030</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81031</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81032</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81033</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81034</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81035</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81036</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81037</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81053</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81054</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81006</name>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81007</name>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81008</name>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81050</name>
      <address>
        <city>Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81010</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81011</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81012</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81013</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81014</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81015</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81016</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81017</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81018</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81019</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81020</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81021</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP81022</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR00001</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR00002</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR00003</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR00004</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR00005</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2016</study_first_submitted>
  <study_first_submitted_qc>January 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2016</study_first_posted>
  <last_update_submitted>August 31, 2017</last_update_submitted>
  <last_update_submitted_qc>August 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tamsulosin</keyword>
  <keyword>Overactive bladder</keyword>
  <keyword>Benign prostatic hypertrophy</keyword>
  <keyword>Mirabegron</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamsulosin</mesh_term>
    <mesh_term>Mirabegron</mesh_term>
    <mesh_term>Adrenergic alpha-Antagonists</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

